QPPV.COM

What Is the Reference Member State (RMS) in EU Regulatory Affairs?

A textbook-quality guide to the Reference Member State (RMS), explaining its legal role, responsibilities, relationship with CMSs and CMDh, and practical significance for regulatory affairs and pharmacovigilance.

Audio Lesson 10 min
Knowledge Assessment Test your understanding of this article. Take the assessment →

What Is the Reference Member State (RMS) in EU Regulatory Affairs?

Introduction

The Reference Member State (RMS) is the Member State that leads the assessment of a medicinal product in a mutual-recognition procedure (MRP) or decentralised procedure (DCP).

That definition is accurate, but it does not fully explain the importance of the role.

The RMS sits at the centre of a regulatory structure that combines:

The RMS is therefore neither:

It is a Member State regulatory authority performing a defined coordinating and assessment function within an EU procedure.

EMA defines the RMS as the EU Member State that leads the review of an application in a mutual-recognition or decentralised procedure. 1

The legal basis is found principally in Article 28 of Directive 2001/83/EC.

Article 28 requires an applicant seeking authorisation in more than one Member State to request one Member State to act as the RMS and to prepare an assessment report. 2

A useful mental model is:

Applicant
    |
    v
RMS
    |
    +------------------+
    |                  |
    v                  v
  CMS 1              CMS 2
    |                  |
    +--------+---------+
             |
             v
    Coordinated regulatory
         procedure
             |
             v
    National marketing
      authorisations

The RMS coordinates the scientific and procedural work.

The CMSs retain their own regulatory responsibilities.

1. Where Does the RMS Fit in the EU Regulatory System?

The RMS exists specifically within the framework for nationally authorised medicines covered by MRP or DCP.

It should therefore be distinguished from the structures used for centrally authorised medicines.

For a centrally authorised medicine:

Applicant
   |
   v
  EMA
   |
   v
 CHMP
   |
   v
European Commission
   |
   v
Union marketing
  authorisation

For an MRP or DCP medicine:

Applicant
   |
   v
  RMS
   |
   v
CMSs
   |
   v
National marketing
  authorisations

The distinction is important.

The RMS is not the equivalent of EMA.

Nor is the RMS equivalent to CHMP.

The RMS is a national competent authority acting within a coordinated European procedure.

2. The Legal Basis for the RMS

Article 28 of Directive 2001/83/EC establishes the framework for applications seeking marketing authorisation in more than one Member State.

The applicant submits an application based on an identical dossier in the relevant Member States.

The applicant then requests one Member State to act as the RMS and prepare an assessment report.

Where the medicinal product is already authorised, the procedure operates through mutual recognition.

Where the medicinal product has not yet been authorised in the EU, the decentralised procedure provides the mechanism for coordinated assessment. 3

The RMS is therefore not merely a convention developed by regulators.

It is a defined role within the EU legal framework.

3. What Does "Reference" Mean?

The word "reference" can be misleading.

It does not mean that the RMS becomes the sole regulator for the product.

Instead, the RMS provides the principal scientific and procedural reference point for the participating Member States.

The assessment performed by the RMS becomes the foundation for the coordinated procedure.

The CMSs then review and participate in the procedure under the applicable legal framework.

Thus:

Reference does not mean exclusive authority.

It means that one Member State is designated to lead and coordinate the assessment.

4. RMS in the Decentralised Procedure

The RMS has a particularly visible role in the DCP.

In a DCP:

The simplified sequence is:

No existing EU MA
       |
       v
    DCP
       |
       v
 Applicant selects
      RMS
       |
       v
 RMS assessment
       |
       v
  CMS review
       |
       v
   Agreement
       |
       v
National MAs issued
in participating MSs

The RMS is therefore central to creating the scientific basis for the subsequent national authorisations.

5. RMS in the Mutual-Recognition Procedure

The role is slightly different in an MRP because an authorisation already exists.

The starting point is:

Existing national MA
         |
         v
        RMS
         |
         v
 Assessment report
  prepared/updated
         |
         v
       CMSs
         |
         v
   Recognition
         |
         v
  National MAs in
  additional MSs

Article 28 provides that where a medicinal product has already received a marketing authorisation, the concerned Member States recognise the marketing authorisation granted by the RMS. The MAH requests the RMS to prepare or, where necessary, update the assessment report. 4

This is one of the fundamental differences between MRP and DCP.

6. The RMS and the Assessment Report

One of the most important RMS responsibilities is the preparation and maintenance of the assessment report.

The assessment report records the scientific evaluation of the medicinal product.

Depending on the application and procedure, it addresses the evidence supporting:

The assessment report provides the scientific basis for the participating Member States to consider the application.

It is therefore more than a summary.

It represents the structured regulatory reasoning supporting the proposed authorisation.

7. What Does the Assessment Report Do?

The assessment report performs several functions.

It:

  1. documents the scientific assessment;
  2. explains the regulatory conclusions;
  3. provides the CMSs with the basis for their review;
  4. supports discussion of outstanding questions;
  5. provides a reference for the agreed regulatory position;
  6. can support later regulatory work.

The report should therefore be scientifically coherent and sufficiently reasoned to allow other competent authorities to understand the assessment.

8. The RMS Is Responsible for Coordination, Not Just Assessment

It is tempting to think of the RMS as simply the authority that writes the assessment report.

The role is broader.

The RMS also coordinates the regulatory process.

This can involve:

The exact operational responsibilities depend on the procedure and applicable guidance.

The broader principle is:

The RMS connects the scientific assessment with the procedural coordination required to reach an agreed outcome.

9. RMS and CMS: Different Roles

The relationship can be summarised as:

RMS CMS
Leads the assessment Reviews the assessment
Prepares or maintains the assessment report Provides comments and scientific review
Coordinates the procedure Participates in the coordinated procedure
Communicates the assessment position Raises questions or concerns
Facilitates agreement Seeks agreement within the applicable framework
Coordinates regulatory documentation Implements the resulting national authorisation

This does not mean that CMSs are passive.

They retain an important scientific and regulatory role.

10. CMSs Can Challenge the RMS

The RMS does not have unilateral authority to dictate the scientific conclusion.

CMSs review the assessment and can raise questions.

If a CMS identifies a concern, the RMS and CMSs must work through the applicable procedure.

This is a critical feature of the European system.

The model is based on:

coordinated assessment and mutual reliance, not blind acceptance.

11. What If the RMS and CMSs Disagree?

Most procedures are intended to reach agreement.

But disagreement can occur.

For an MRP or DCP, a CMS may consider that it cannot approve:

on the grounds of a potential serious risk to public health.

Article 29 of Directive 2001/83/EC provides the relevant mechanism. The Member State must provide a detailed explanation of its position, and the points of disagreement are referred to the coordination group. 5

This is a major responsibility of the RMS:

to coordinate the procedure when scientific or regulatory disagreement arises, rather than simply declaring the assessment complete.

12. The RMS and CMDh

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) is the European coordination body relevant to nationally authorised human medicines within the MRP/DCP framework.

EMA describes CMDh as examining questions concerning marketing authorisations in two or more Member States under MRP or DCP, as well as certain variations to those marketing authorisations. 6

The RMS interacts with this broader coordination system when the applicable procedure requires it.

For example, where Member States disagree on a potential serious risk to public health during an MRP/DCP, CMDh considers the matter and seeks agreement within the applicable period. 7

13. The RMS Does Not Replace CMDh

Another common misconception is that the RMS and CMDh perform the same function.

They do not.

RMS

Leads a specific product procedure.

CMDh

Provides coordination across Member States for questions concerning MRP/DCP medicines within its remit.

The relationship can be represented as:

Specific product
      |
      v
    RMS
      |
      v
MRP / DCP procedure
      |
      v
If coordination issue
      |
      v
    CMDh

The RMS is therefore product-procedure specific.

CMDh has a broader coordination function.

14. The RMS and National Competent Authority

The RMS is a Member State authority.

The role is normally performed by the national competent authority or the relevant national regulatory organisation designated within the Member State.

Therefore, it is useful to distinguish:

RMS

from:

the national regulatory authority as an institution.

The same authority may act as RMS for one product and CMS for another.

Its role depends on the particular procedure.

15. A Member State Can Be RMS for One Product and CMS for Another

This is an important practical point.

The RMS designation is not a permanent status for a Member State.

For Product A:

France = RMS
Germany = CMS
Spain = CMS

For Product B:

Germany = RMS
France = CMS
Spain = CMS

The designation is procedure-specific.

Therefore, regulatory databases should store RMS and CMS information at the appropriate product/procedure level.

16. How Is the RMS Selected?

The applicant requests one Member State to act as RMS.

In practice, the choice can involve:

The precise arrangements for requesting an authority to act as RMS can differ according to national procedures.

CMDh provides procedural guidance and national information concerning requests to act as RMS in DCPs. 8

Therefore, an applicant should not assume that any Member State can automatically be selected without regard to the relevant national process.

17. RMS Selection Is a Regulatory Decision

RMS selection should be treated as a strategic regulatory decision rather than a trivial administrative choice.

A good RMS relationship can affect:

The choice does not change the underlying scientific standard.

But it can materially affect how the procedure is managed.

18. The RMS and Regulatory Communication

The RMS often becomes a central communication channel between:

Communication should therefore be:

The RMS should not be treated as a substitute for formal regulatory requirements.

Formal submissions and responses must follow the applicable procedural channels.

19. The RMS and Applicant Questions

During assessment, questions may arise concerning:

The RMS coordinates the assessment process and communicates the consolidated regulatory position according to the procedure.

The applicant's responses then become part of the continuing scientific assessment.

This creates a cycle:

RMS assessment
      |
      v
   Questions
      |
      v
   Applicant
   response
      |
      v
 RMS assessment
      |
      v
  CMS review
      |
      v
   Agreement

This iterative process is a normal feature of regulatory assessment.

20. RMS and Benefit-Risk Assessment

The RMS has an important role in integrating the evidence into an overall benefit-risk conclusion.

The assessment should not simply list:

It must consider the relationship between them.

A simplified model is:

Clinical benefit
      +
Known and potential risks
      +
Uncertainties
      +
Risk-minimisation measures
      |
      v
  Benefit-risk
   conclusion

This conclusion becomes part of the scientific basis for the proposed regulatory outcome.

21. Pharmacological Plausibility in an RMS Assessment

Pharmacological plausibility can be relevant when evaluating a safety concern.

For example, if a medicinal product affects a physiological pathway that could plausibly contribute to a reported adverse event, this may strengthen the biological coherence of the hypothesis.

But the RMS should distinguish:

Established evidence

from:

supportive evidence

from:

biological plausibility

from:

speculation.

A plausible mechanism is not proof of causality.

The strongest assessment integrates mechanistic information with:

This distinction is fundamental to high-quality safety assessment.

22. Example: A New Safety Signal During a DCP

Consider a medicine undergoing DCP.

During assessment, new information suggests a possible serious adverse reaction.

The scientific question is initially:

Does the available evidence support a causal association?

The RMS may need to consider:

The important point is that:

The RMS is not simply an administrative coordinator when safety information affects the scientific assessment.

The assessment must remain scientifically reasoned.

23. RMS and Product Information

The RMS coordinates development and agreement of the product information within the MRP/DCP framework.

This includes:

Where a safety concern is identified, the product information may need to change.

For example, the assessment may support:

The exact change must be supported by the scientific and regulatory assessment.

24. RMS and Risk Management

Risk-management information can also become relevant to the RMS role.

Depending on the product and procedure, the regulatory assessment may consider:

The RMS therefore needs to understand the relationship between the clinical evidence, safety profile and proposed risk-management framework.

25. RMS and Variations

The RMS role does not necessarily end when the initial authorisation is granted.

For MRP/DCP products, the RMS can have an important role in subsequent regulatory procedures.

For example, the EU variations framework provides mechanisms under which the RMS may act as the reference authority for relevant procedures involving nationally authorised products. EMA guidance specifically identifies the RMS in the context of MRP/DCP marketing authorisations for certain variation-related work. 9

This means that the RMS can remain an important regulatory reference point throughout the product lifecycle.

26. RMS and Post-Authorisation Changes

After authorisation, the product may undergo changes involving:

Some changes are purely national.

Others require coordinated procedures.

The regulatory pathway depends on the nature of the change.

The RMS role is therefore best understood as part of an ongoing regulatory relationship rather than a one-time assessment role.

27. RMS and Safety Changes

Suppose a post-authorisation safety issue requires a Type II variation affecting an MRP/DCP product.

The RMS may become involved in the assessment under the applicable procedure.

The scientific question may be:

Does the new evidence justify changing the authorised conditions of use?

The regulatory assessment can involve:

New evidence
      |
      v
Safety assessment
      |
      v
Benefit-risk review
      |
      v
RMS assessment
      |
      v
CMS coordination
      |
      v
Agreed regulatory change

The exact procedure depends on the regulatory circumstances.

28. RMS and Referral Procedures

The RMS should also be distinguished from an EU referral authority or committee.

A referral is a separate legal mechanism.

For example, EMA explains that safety-related referrals involving nationally authorised medicines can be assessed by PRAC and then, depending on the procedure and products affected, by CMDh or CHMP. 10

Therefore:

RMS involvement does not mean that every safety issue remains an RMS-only matter.

A safety concern can escalate into a broader EU procedure where the applicable legal criteria are met.

29. Article 29(4): When the RMS Becomes the Gateway to Escalation

Article 29(4) provides a particularly clear example.

If Member States fail to reach agreement during the CMDh process concerning an MRP or DCP application because of a potential serious risk to public health, the RMS refers the matter to the Agency. 11

The sequence is:

MRP / DCP
     |
     v
   RMS
     |
     v
CMS disagreement
     |
     v
   CMDh
     |
     v
No agreement
     |
     v
Article 29(4)
   referral
     |
     v
    EMA
     |
     v
   CHMP

This demonstrates that the RMS can be an important procedural bridge between the national coordination stage and a Union-level procedure.

30. The RMS Does Not Decide Article 29(4) Alone

Another important distinction:

The RMS does not unilaterally determine that an Article 29(4) referral should occur simply because it disagrees with a CMS.

The legal conditions must be satisfied.

EMA states that an Article 29(4) referral applies where Member States fail to reach agreement during the Article 29 coordination procedure on an MRP or DCP application on the grounds of a potential serious risk to public health. 12

The procedural threshold therefore matters.

31. RMS and the 60-Day CMDh Process

When the relevant disagreement is referred to CMDh, the group seeks agreement within the applicable period.

EMA describes the CMDh as striving to reach agreement within 60 days where Member States disagree on the grounds of a potential serious risk to public health. 13

This creates a structured escalation path rather than an informal dispute.

The RMS participates in this system but does not replace the CMDh.

32. RMS Versus Rapporteur

The RMS should not be confused with the rapporteur in the centralised procedure.

RMS

CHMP rapporteur

The terminology is similar because both roles involve scientific assessment.

The legal and institutional contexts are different.

33. RMS Versus CHMP

The distinction is even more important here.

RMS

Works within MRP/DCP.

CHMP

Committee responsible for scientific assessment of centrally authorised human medicines and specified EU procedures.

An RMS can therefore interact with European committees without becoming part of CHMP's institutional role.

34. RMS Versus CMDh

The distinction can be remembered as:

RMS = lead authority for a particular procedure.

CMDh = coordination group for the MRP/DCP regulatory system.

The RMS deals with the product-specific assessment.

CMDh deals with coordination across Member States within its remit.

35. RMS and the Regulatory Master File

For an MAH, the RMS should be captured in regulatory master data.

Useful fields include:

Field Example
Product Medicinal product
Procedure DCP
Procedure number DCP/XX/XXXX
RMS Member State authority
CMSs Participating Member States
MAH Legal entity
Current MA status Authorised
Current product information Version/date
Relevant variations Procedure history
Relevant referrals If applicable

The exact fields should be adapted to the organisation's regulatory system.

The principle is traceability.

36. Why Regulatory Data Quality Matters

If the RMS information is incorrect, several downstream processes can be affected.

For example:

This is why regulatory master data should be controlled.

The RMS is not merely a contact name.

It is part of the legal and procedural identity of the product.

37. RMS and Pharmacovigilance Systems

A pharmacovigilance system should be able to connect safety information to the correct regulatory context.

For MRP/DCP products, that includes understanding:

This allows a safety assessment to answer not only:

"What does the evidence show?"

but also:

"Which regulatory framework applies to this product?"

38. RMS and QPPV Oversight

The QPPV does not normally become the operational owner of the RMS relationship.

However, the QPPV should understand its significance.

When a safety issue emerges, the QPPV may need to know:

The QPPV's role is therefore one of pharmacovigilance oversight rather than substitution for Regulatory Affairs.

39. A Worked QPPV Example

Suppose an MAH has a DCP product authorised in ten Member States.

A serious safety signal emerges.

The QPPV asks:

  1. Which products are affected?
  2. Which Member States are authorised?
  3. Who is the RMS?
  4. Which CMSs are involved?
  5. What is the current product information?
  6. Does the signal concern an existing important risk?
  7. Does it represent a new or changed risk?
  8. Could the benefit-risk balance be affected?
  9. Is regulatory action required?
  10. Does the issue require coordination beyond the RMS?

The RMS information therefore forms part of the regulatory context for the pharmacovigilance decision.

40. A Worked Variation Example

Imagine that new safety evidence supports adding a contraindication.

The MAH determines that the change affects an MRP/DCP product across several Member States.

The organisation must establish the appropriate variation procedure.

The regulatory team identifies:

The RMS then plays its defined role in the coordinated procedure.

This demonstrates why regulatory lifecycle management and pharmacovigilance cannot be separated completely.

41. What the RMS Is Not

The RMS is not:

It is:

the designated Member State authority leading the assessment in an MRP or DCP.

That distinction prevents considerable regulatory confusion.

42. Common Misconception: RMS Means the Product Is "Owned" by That Country

Not in a commercial sense.

The RMS is a procedural regulatory role.

The product may be authorised in multiple Member States.

The MAH remains responsible for the product.

The participating national authorities retain their respective regulatory responsibilities.

The RMS simply has the designated lead role.

43. Common Misconception: CMSs Must Accept Everything the RMS Says

Incorrect.

CMSs review the assessment and can raise concerns.

The system is designed to facilitate agreement while preserving national regulatory participation.

Where a CMS identifies a potential serious risk to public health and agreement cannot be reached, the legal escalation mechanism can apply. 14

44. Common Misconception: RMS Means EMA Is Not Involved

Not necessarily.

EMA is not the routine assessor for every MRP/DCP application.

However, EMA can become involved in specified Union procedures, including referrals.

The RMS therefore operates within a broader European regulatory network.

45. Common Misconception: The RMS Role Ends at Authorisation

Incorrect.

The RMS can remain relevant for post-authorisation procedures, including certain variations and other coordinated regulatory activities.

EMA's variation guidance specifically identifies the RMS as the reference authority for relevant MRP/DCP marketing-authorisation procedures. 15

46. Common Misconception: The RMS Is Always the Same for a Company

Incorrect.

A company can have:

The role belongs to the specific procedure.

47. Inspection Perspective

An inspection may not ask:

"Define RMS."

It may instead test whether the organisation actually understands the RMS structure.

For example:

The inspection expectation is therefore operational knowledge.

48. Documentation That Should Be Traceable

For an MRP/DCP product, an organisation should be able to trace, as applicable:

The exact documentation set depends on the product and procedure.

The principle is:

The regulatory history should be reconstructable.

49. RMS and Auditability

A strong regulatory system should allow an auditor or inspector to move backwards:

Current product information
          |
          v
   Latest variation
          |
          v
   Previous assessment
          |
          v
     RMS decision
          |
          v
    Original procedure
          |
          v
   Initial assessment

This traceability allows the organisation to demonstrate how the current regulatory position was established.

50. RMS and Scientific Challenge

Good regulatory assessment should not mean automatic agreement.

The RMS should be capable of explaining:

The existence of scientific challenge is not evidence that the system failed.

In a mature regulatory system:

challenge improves the quality of the final assessment.

51. A Useful Evidence Hierarchy

When assessing a safety concern within an RMS-led procedure, it is useful to separate:

Established

Supported by strong and reproducible evidence.

Supported

Multiple evidence streams point in the same direction.

Plausible

Biologically credible but not established.

Uncertain

Evidence is insufficient or conflicting.

Unsupported

The available evidence does not substantiate the proposed interpretation.

This vocabulary is particularly useful in regulatory writing because it prevents mechanistic speculation from being presented as fact.

52. A Practical RMS Workflow

A simplified workflow is:

Application
    |
    v
RMS designated
    |
    v
Scientific assessment
    |
    v
Assessment report
    |
    v
CMS review
    |
    v
Questions / comments
    |
    v
Applicant responses
    |
    v
Updated assessment
    |
    v
Agreement
   / \
  /   \
Yes    No
 |      |
 v      v

National CMDh / MA escalation | v Possible Union procedure

This is a teaching model.

The precise timelines and procedural steps depend on the application and legal framework.

53. RMS and the Product Lifecycle

The RMS should be viewed as part of the regulatory lifecycle:

Initial application
      |
      v
    RMS
      |
      v
  Authorisation
      |
      v
   Variations
      |
      v
 Safety changes
      |
      v
   Regulatory
   reassessment
      |
      v
   Continued
   oversight

The role and intensity of RMS involvement can change over time.

54. Why the RMS Concept Matters Beyond Regulatory Affairs

At first glance, RMS appears to be a Regulatory Affairs concept.

It is actually relevant to:

Any function that needs to understand the regulatory status of a nationally authorised medicine may need to understand the RMS structure.

55. A Practical Question for Every MRP/DCP Product

For every MRP/DCP product, ask:

Who is the RMS, which Member States are CMSs, and what is the current procedural status?

This single question can prevent several downstream errors.

It can also be extended:

What procedure created the authorisation, what regulatory changes have occurred since then, and which authority coordinates the current regulatory work?

That is a much more useful question than simply asking:

"Is the product authorised?"

56. RMS Versus Reference Authority

The term "reference authority" can appear in other EU regulatory procedures.

It should not automatically be equated with RMS.

For example, the EU variations framework can use a reference authority concept for worksharing.

The correct role depends on the specific procedure.

Therefore, regulatory databases should not collapse:

into one generic field.

These roles can overlap institutionally while remaining legally distinct.

57. RMS and Worksharing

Worksharing is another example where regulatory roles can overlap.

EMA explains that worksharing can involve centrally authorised products, MRP/DCP products and purely national marketing authorisations, with one authority acting as the reference authority for the assessment of certain variations on behalf of other authorities. 16

This does not mean that the reference authority in every worksharing procedure is automatically the RMS.

The procedure determines the role.

This is an important distinction for regulatory master-data design.

58. A Regulatory Data Model

For sophisticated regulatory systems, the product should ideally be represented as:

Product
   |
   +-- Authorisation route
   |
   +-- Procedure number
   |
   +-- RMS
   |
   +-- CMSs
   |
   +-- National MAs
   |
   +-- Product information
   |
   +-- Variations
   |
   +-- Referrals
   |
   +-- Safety restrictions
   |
   +-- Regulatory commitments

This model is much more robust than storing only:

"EU authorised."

59. Why This Matters for Signal Management

A safety signal may begin with a single case.

The scientific assessment asks:

Is there evidence of a causal association?

The regulatory assessment then asks:

Does the evidence change the regulatory understanding of the product?

The procedural assessment then asks:

Which authorities and legal mechanisms must act?

For an MRP/DCP product, RMS and CMS information becomes important at this third level.

Thus:

Signal
  |
  v
Scientific assessment
  |
  v
Regulatory significance
  |
  v
Authorisation structure
  |
  v
RMS / CMS / EU procedure

This is why signal management and regulatory affairs should not operate as disconnected systems.

60. The RMS and Emerging Safety Issues

If a safety concern becomes urgent, the organisation should not assume that the RMS alone determines the response.

The organisation should first establish:

The RMS may be an important authority in the subsequent regulatory process.

But the correct pathway depends on the legal framework and the nature of the concern.

61. Example: A Potential Serious Risk to Public Health

Suppose a CMS identifies evidence suggesting a potential serious risk to public health during a DCP.

The CMS provides detailed reasons.

The RMS coordinates the procedure.

If the Member States cannot reach agreement within the applicable CMDh process, the matter can proceed to an Article 29(4) referral under the conditions established by the Directive. EMA confirms that Article 29(4) applies to disagreements during MRP/DCP on the grounds of a potential serious risk to public health. 17

This is a good example of why the RMS role should be understood as part of a system rather than in isolation.

62. The RMS in One Sentence

If the entire article had to be reduced to one sentence:

The Reference Member State is the designated EU Member State authority that leads the scientific and procedural assessment of a medicinal product in a mutual-recognition or decentralised procedure and coordinates that assessment with the participating Concerned Member States.

Everything else follows from that role.

63. Key Takeaways

RMS = lead Member State authority for a specific MRP/DCP procedure.

CMS = participating Member State reviewing and implementing the coordinated outcome.

CMDh = European coordination group for the MRP/DCP system.

References

  1. European Medicines Agency. Reference Member State. EMA glossary. Defines the RMS as the EU Member State leading review of an application in an MRP or DCP.
    https://www.ema.europa.eu/en/glossary-terms/reference-member-state

  2. European Parliament and Council. Directive 2001/83/EC of 6 November 2001 on the Union code relating to medicinal products for human use, as amended. Article 28 establishes the RMS role and the assessment-report framework; Article 29 establishes the disagreement mechanism.
    https://eur-lex.europa.eu/eli/dir/2001/83/2022-01-01/eng

  3. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Describes the role and functions of CMDh in MRP/DCP medicines and disagreement procedures.
    https://www.ema.europa.eu/en/committees/working-parties-other-groups/coordination-group-mutual-recognition-decentralised-procedures-human-cmdh

  4. European Medicines Agency. Concerned Member State. Defines the CMS and its relationship with the RMS.
    https://www.ema.europa.eu/en/glossary-terms/concerned-member-state

  5. European Medicines Agency. Questions and answers: Article 29(4) referral procedures. Describes the legal and procedural circumstances under which an Article 29(4) referral may follow disagreement during an MRP or DCP.
    https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/questions-and-answers-article-294-referral-procedures

  6. European Medicines Agency. Referral procedures: human medicines. Explains the relationship between nationally authorised medicines, CMDh, PRAC, CHMP and Union referral procedures.
    https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines

  7. European Medicines Agency. Pre-authorisation guidance. Provides access to EU procedural guidance, including Notice to Applicants Volume 2A covering marketing authorisation and mutual-recognition procedures.
    https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance

  8. Heads of Medicines Agencies / CMDh. Decentralised Procedure. Provides procedural guidance, RMS request information, templates and other practical material concerning DCP.
    https://www.hma.eu/human-medicines/cmdh/procedural-guidance/application-for-ma/dcp.html

  9. European Medicines Agency. Procedural advice on unforeseen variations. Describes the role of the RMS in relevant MRP/DCP variation procedures and the relationship with the Variation Regulation.
    https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-recommendations-unforeseen-variations-according-article-5-commission-regulation-ec-no-12342008_en.pdf

  10. European Medicines Agency. Worksharing: questions and answers. Explains the use of a reference authority for certain variation worksharing procedures and distinguishes this role from the general MRP/DCP framework.
    https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/variations-including-extensions-marketing-authorisations/worksharing-questions-answers

  11. European Medicines Agency. Authorisation of medicines. Provides an overview of the EU authorisation routes and explains the relationship between centralised, national, MRP and DCP routes.
    https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines

Regulatory interpretation note

This article is an educational explanation of the Reference Member State within the EU regulatory system. It does not replace Directive 2001/83/EC, Regulation (EC) No 726/2004, Commission decisions, EMA guidance, CMDh guidance, national legislation or product-specific regulatory advice.

The exact responsibilities and procedural steps applicable to an RMS depend on the type of procedure, the medicinal product, the stage of the regulatory lifecycle and the applicable legislation and guidance.

The terms RMS, CMS, CMDh, CHMP, PRAC and reference authority describe different regulatory roles and should not be treated as interchangeable.

The simplified diagrams and workflows are teaching aids rather than legal flowcharts.

Scientific mechanisms and pharmacological plausibility should be distinguished from established causal evidence. A plausible biological mechanism can support an assessment but does not by itself establish causality.

Because EU pharmaceutical legislation and procedural guidance can change, current primary legislation and official EMA, European Commission, CMDh and national competent-authority guidance should be consulted when making regulatory decisions.

Revision History

Related Articles

What Is a Concerned Member State (CMS) in EU Regulatory Affairs?

A detailed guide to the Concerned Member State (CMS), explaining its legal and scientific role in MRP and DCP, relationship with the RMS, participation in regulatory decisions, and significance for pharmacovigilance and regulatory affairs.

How RMS and CMS Roles Work Together in MRP and DCP

Explains the division of assessment, review, coordination, communication and decision-making responsibilities between the RMS and CMSs without duplicating dedicated RMS and CMS articles.

What Happens When Member States Disagree During an MRP or DCP?

Explains how a CMS objection develops into a formal disagreement, the role of the coordination group, the applicant's involvement and the transition to an EU-level procedure when agreement cannot be reached.